SecBot SecBot
6-K ·Filed May 5, 2026

SOPH

SOPHiA GENETICS SA
MIXED
Impact 6/10
Horizonweeks Processed5mo ago SEC0001840706-26-000177
Notable filing: 6-K
Actionable Insight ◆ Mixed

Strong 22% revenue growth and improving NDR (117%) signal accelerating commercial momentum, but widening losses and $15.1M quarterly cash burn raise sustainability questions. Monitor the Guardant Health patent litigation outcome in the UK and EU, which could impact MSK-Access liquid biopsy revenue. The $54.9M cloud hosting commitment and $50M debt with SOFR+6.25% interest create fixed cost pressure. The stock may trade on revenue trajectory vs. cash runway; watch Q2 for evidence of operating leverage from the April headcount reduction.

DirectionMixed
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
SOPH ▲ +13.61% at T+60d
NEUTRAL call +13.61% · α vs SPY +10.87% · entry $5.07 → $5.76
Entry = T+0 close
May 5, 2026
via day close
T+1d
-0.99%
call -0.99% · α -2.37%
$5.02
settled 6mo ago
T+5d
-8.68%
call -8.68% · α -10.66%
$4.63
settled 6mo ago
T+20d
-2.56%
call -2.56% · α -7.52%
$4.94
settled 5mo ago
T+60d
+13.61%
call +13.61% · α +10.87%
$5.76
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

SOPHiA GENETICS reported Q1 2026 revenue of $21.7 million, up 22% YoY, driven by 16% growth in platform analysis volume and a $1.5 million FX benefit. However, the IFRS net loss widened to $19.3 million (from $17.4 million) as operating expenses grew 13%, including $0.7 million in Guardant litigation costs. The company reaffirmed FY 2026 revenue guidance of $92-$94 million and expects to approach adjusted EBITDA breakeven by end of 2026. The strong top-line growth is offset by deepening losses and ongoing patent litigation risk.

Key Facts

  • Q1 2026 revenue: $21.7 million, up 22% YoY from $17.8 million
  • IFRS net loss: $19.3 million, up 11% YoY from $17.4 million
  • Adjusted EBITDA loss: $9.2 million, improving 3% YoY from $9.5 million
  • Platform analysis volume: 107,576, up 16% YoY
  • Core genomics customers: 537, up from 490 YoY
  • Net dollar retention: 117%, up from 103% YoY
  • Cash and cash equivalents: $65.4 million, down from $70.3 million at Dec 31, 2025
  • FY 2026 guidance reaffirmed: revenue $92-$94 million, adjusted EBITDA loss $29-$32 million
  • Guardant Health patent litigation ongoing; $0.7 million in legal expenses in Q1
  • ATM offering raised $14.5 million net proceeds in Q1 2026

Financial Impact

Revenue grew $3.9M YoY, but net loss increased $1.9M. Cash burn from operations was $15.1M in Q1.

revenuenet losscashadjusted EBITDA

Risk Factors

  • Guardant Health patent litigation could result in injunctive relief blocking MSK-Access sales in UK/EU
  • Cash burn of $15.1M per quarter with $65.4M cash on hand implies ~4 quarters of runway without additional financing
  • $54.9M minimum cloud hosting commitment through 2030 creates fixed cost overhang
  • Potential loss of FPI status could increase compliance costs and require additional exchange listings
  • Interest expense on $50M debt at SOFR+6.25% will increase if rates rise

Market Snapshot

Exchange
Nasdaq
Sector
Services-Computer Processing & Data Preparation
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Software & IT

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001840706-26-000177
Document: sophiageneticssaex993q12026.htm0001840706-26-000177
Document: sophiageneticssaex992q12026.htm0001840706-26-000177
Document: q12026sophiageneticssa6-k.htm0001840706-26-000177
Document: 0001840706-26-000177-index-headers.html0001840706-26-000177
Document: 0001840706-26-000177-index.html0001840706-26-000177
Document: 0001840706-26-000177.txt0001840706-26-000177
39 reports for SOPH
Performance horizon
50% Hit rate @ T+5 5 of 10 directional calls Went positive at some point 8 of 10 best @ T+60▲ +64.11%Jun 4, 2026
Filters
Rows
Reports for SOPH — sortable, filterable
TypeNow
Oct 14, 2026
13d ago
Insider Cluster
NEUTRAL ★ 2/10
$7.29 $7.05▼ −3.29%▼ −2.28%$7.52 (+3.16%)
Oct 5, 2026
21d ago
144
NEUTRAL ★ 2/10
$7.38 $7.09▼ −3.93%▼ −3.79%$7.52 (+1.90%)
Sep 16, 2026
5w ago
Insider Cluster
NEUTRAL ★ 2/10
$8.53 $8.26▼ −3.17%▼ −4.02%$7.52 (−11.84%)
Sep 14, 2026
6w ago
Insider Cluster
NEUTRAL ★ 2/10
$7.96 $8.07▲ +1.38%▼ −0.73%$7.52 (−5.53%)
Aug 31, 2026
8w ago
Insider Cluster
NEUTRAL ★ 3/10
$8.43 $7.68▼ −8.84%▼ −8.92%$7.52 (−10.74%)
Aug 26, 2026
8w ago
Insider Cluster
NEUTRAL ★ 2/10
$8.92 $8.30▼ −6.95%▼ −7.22%$7.52 (−15.70%)
Aug 25, 2026
8w ago
144
BEARISH ★ 4/10
$8.53 $8.28▲ +2.93%▲ +2.81%$7.52 (+11.84%)
Aug 21, 2026
9w ago
Insider Cluster
NEUTRAL ★ 4/10
$8.45 $8.40▼ −0.59%▼ −1.06%$7.52 (−11.01%)
Aug 21, 2026
9w ago
Insider Cluster
NEUTRAL ★ 4/10
$8.45 $8.40▼ −0.59%▼ −1.06%$7.52 (−11.01%)
Aug 14, 2026
10w ago
Insider Cluster
BEARISH ★ 5/10
$7.63 $8.45▼ −10.75%▼ −11.94%$7.52 (+1.44%)
Showing 10 of 39

US Market Status

Market Closed — Opens in 6h 51m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 5, 2026